Patient P-01413

Synthetic patientNBL-101 · Day 104 · 65–74 · M · baseline S14Steering view · 3D Open companion preview

Therapy response

Stable

Tolerance

Deteriorating

GI state

Stable

Inflammatory state

Deteriorating

Nutritional resilience

Stable

Discontinuation risk

67%

Trajectory

Baseline → today → 30-day prediction · hover a day for signals and events

solid = observed · dashed = predicted

Day 0 NBL-101 started — Baseline state S14
Day 52 Trajectory diverged from prediction — Observed response fell below the model's expected path.
Day 59 GI-04 recommended — GI Support Protocol GI-04
Day 60 Patient accepted — Started GI-04 in the companion
Day 63 ME-01 recommended — Monitoring Escalation ME-01
Day 64 Patient accepted — Started ME-01 in the companion
Day 67 Deterioration detected before clinical escalation — Monitoring Escalation ME-01
Day 68 GI symptom burden −34% vs expected — GI Support Protocol GI-04
Day 74 Tolerance state changed — Unstable → Improving

What changed?

Trajectory began diverging from predicted response on Day 52.

Primary contributors, last 14 days

Inflammatory activity+6
Toxicity+5
Treatment adherence-3
GI instability+2

What helped?

GI Support Protocol GI-04Day 59
Result: symptom burden −34%
Monitoring Escalation ME-01Day 63
Result: deterioration detected before clinical escalation

LIFE OS recommendation

Dietary Support Protocol NP-02

61%

probability of meaningful tolerance improvement

284 similar trajectories
66% showed improvement
median effect visible after 10 days

Daily trackers

Molecule settings

The trackers this program marks as important, last 14 days vs the 14 before.

GI burden

Companion

45.4/100

improving · -4.9 vs previous 14 d

Toxicity

Blood

49.1/100

improving · -3.1 vs previous 14 d

Sleep quality

Wearable

57/100

improving · +4.0 vs previous 14 d

Energy level

Daily log

4.1/10

improving · +0.4 vs previous 14 d

Stress level

Daily log

4.9/10

improving · -0.3 vs previous 14 d

Steps

Wearable

7,805

stable · +246 vs previous 14 d

Adherence

Companion

47.5 %

stable · -1.0 vs previous 14 d

This trajectory is decaying — what would help, what would not

Steering view →

Heading towards failing · 33 from the failing basin, 53 from restoration.

Would help

NP-02 Dietary Support Protocol
63% improved among 64 similar · onset 10 d · confidence 74%
SC-12 Supportive Compound
76% improved among 51 similar · onset 6 d · confidence 74%
CR-01 Clinician Review
100% improved among 8 similar · onset 5 d · confidence 74%

Would not help

Keep fat low
GI +5.2 next day on high-intake days · n 20
Keep fibre low
GI +2.8 next day on high-intake days · n 18

State influencers · digestive

Next-day GI change on high-intake vs low-intake days, last 60 days. Attribution from this patient's own log; sensitivity set by their biology.

Dietary fat load
+5.2detractor · 95%
Insoluble fibre
+2.8detractor · 66%
Alcohol
+2.1no signal · 49%
Histamine load
+0.7no signal · 15%
Simple carbohydrates
+0.7no signal · 16%
Spicy / capsaicin
+0.6no signal · 15%

Biological layers

Which pathways look influenced, and by which layer of this person's biology.

Pathways under pressure

Inflammatory signalling ↑70
- DNAIL6 -174 variant raises baseline inflammatory tone
- MicrobiomeBacteroides fragilis expansion
- BloodInflammatory load index 52
Drug metabolism and exposure ↑60
- DNACYP2D6 poor metabolizer → higher exposure
- BloodToxicity index 49
Butyrate / short-chain fatty acid production ↓55
- MicrobiomeButyrate capacity 32/100
- Daily logFibre intake low in recent food logs
Mucosal barrier integrity ↓50
- MicrobiomeAkkermansia low → thinner mucus layer
- Daily logGI symptom score 45 and rising
Autonomic recovery ↑25
- WearableResting HR 80 bpm

DNA

Fictional pharmacogenomic panel

IL6 -174 G/C
Higher inflammatory tone
CYP2D6 Poor metabolizer
Higher exposure at standard dose
MTHFR C677T
Reduced folate turnover

Microbiome

Shannon diversity 3.1 · butyrate capacity 32/100

Akkermansia muciniphilaLow
Faecalibacterium prausnitziiNormal
Bacteroides fragilisHigh
Bifidobacterium longumLow
EnterobacteriaceaeHigh

Wearable, last 14 days

daily evolution fed into the runtime

HRV: 57 ms
Sleep: 7.2 h
Steps: 7,275
Resting HR: 80 bpm

Daily log: GI score 45, nutritional resilience 44, adherence 48.

What this patient sees in NostraAI

The content that steers the trajectory: what to eat, what to do, what to take.

Open companion preview

What to eat

Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
Avoid known triggers for now: fried or oily food, dairy, alcohol

What to do

Track each bowel movement today: time, stool form, urgency, overnight waking
Keep the current walking rhythm
Keep the sleep window steady
Keep hydration steady: small amounts through the day rather than large volumes at once

What to take

Take the scheduled dose as agreed with your care team
Electrolyte solution, one sachet after any loose stool
Fictional demo item: oral nutrition supplement with lunch

284 biologically similar trajectories

Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.

Patient	Similarity	Baseline	Intervention	Outcome	Response today
P-01389	65%	S14	SC-12	improved	46
P-01675	57%	S14	NP-02	improved	38
P-01356	53%	S14	GI-04	improved	42
P-01598	53%	S14	GI-04	no change	45
P-01559	52%	S06	GI-04	improved	42
P-01365	51%	S14	SC-12	improved	49
P-01494	51%	S14	GI-04	improved	42
P-01436	50%	S14	GI-04	improved	38
P-01891	50%	S14	SC-12	improved	41
P-01505	49%	S14	NP-02	improved	41
P-01781	49%	S14	NP-02	improved	45
P-01831	49%	S15	SC-12	improved	49